JP2017169559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017169559A5 JP2017169559A5 JP2017037848A JP2017037848A JP2017169559A5 JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5 JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017037848 A JP2017037848 A JP 2017037848A JP 2017169559 A5 JP2017169559 A5 JP 2017169559A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cell
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 19
- 108090001123 antibodies Proteins 0.000 claims 19
- 210000004027 cells Anatomy 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004962 mammalian cells Anatomy 0.000 claims 3
- 101710007887 DHFR Proteins 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102100005838 DHFR Human genes 0.000 claims 1
- 230000036947 Dissociation constant Effects 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 108020001096 dihydrofolate reductase family Proteins 0.000 claims 1
- 102000004419 dihydrofolate reductase family Human genes 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
Claims (22)
- 新生児FcRnレセプター(FcRn)に特異的な抗体を製造する方法であって、
(i)プロモーターにそれぞれ機能可能に連結している、該抗体の軽鎖可変領域(V L )をコードする第1の核酸および該抗体の重鎖可変領域(V H )をコードする第2の核酸を含む宿主細胞を培養し、該抗体を生産する工程;および
(ii)工程(i)で生産された抗体を回収する工程;
を含み、
ここで、該VLは、
アミノ酸配列TGTGSDVGSYNLVS(配列番号14)を含むVL CDR1、
アミノ酸配列GDSQRPS(配列番号15)を含むVL CDR2、および
アミノ酸配列SSYAGSGIYV(配列番号12)またはASYAGSGIYV(配列番号13)を含むVL CDR3を含み、かつ、
該VHは、
アミノ酸配列EYAMG(配列番号22)を含むVH CDR1、
アミノ酸配列SIGSSGGQTKYADSVKG(配列番号23)を含むVH CDR2、
アミノ酸配列LAIGDSY(配列番号24)を含むVH CDR3を含む、
方法。 - 前記VLが、配列番号10または配列番号11と少なくとも85%の相同性を有するアミノ酸配列を含む、請求項1に記載の方法。
- 前記VLが、配列番号10または配列番号11のアミノ酸配列を含む、請求項2に記載の方法。
- 前記VHが、配列番号9と少なくとも85%同一であるアミノ酸配列を含む、請求項1〜3のいずれか一項に記載の方法。
- 前記VHが配列番号9のアミノ酸配列を含む、請求項4に記載の方法。
- 前記第2の核酸が、配列番号17のC末端リジン残基に対応する位置に欠失を有する、重鎖定常領域(C H )をさらにコードする、請求項1〜5のいずれか一項記載の方法。
- 前記C H が、配列番号26のアミノ酸配列を含む、請求項6に記載の方法。
- 前記抗体が、10nM未満の解離定数(KD)でヒトFcRnと結合する、請求項1〜7のいずれか一項に記載の方法。
- 前記抗体が、完全長抗体である、請求項1〜8のいずれか一項に記載の方法。
- 前記抗体が、ヒト抗体もしくはヒト化抗体であるか、または、ヒトにおいて非免疫原性である、請求項1〜9のいずれか一項に記載の方法。
- 前記抗体が、ヒト抗体フレームワーク領域を含む、請求項1〜10のいずれか一項に記載の方法。
- 前記抗体が、マウス抗体である、請求項1〜9のいずれか一項に記載の方法。
- 前記抗体が、キメラ抗体である、請求項1〜9のいずれか一項に記載の方法。
- 前記抗体が、Fab、F(ab)'2、Fv、およびscFvからなる群から選択される、請求項1〜9のいずれか一項に記載の方法。
- 前記抗体が、モノクローナル抗体である、請求項1〜14のいずれか一項に記載の方法。
- 前記第1の核酸および前記第2の核酸が、同じ発現ベクター上にある、請求項1〜15のいずれか一項記載の方法。
- 前記第1の核酸および前記第2の核酸が、2つの異なる発現ベクター上にある、請求項1〜15のいずれか一項記載の方法。
- 前記宿主細胞が、菌細胞、酵母細胞、昆虫細胞、植物細胞、または哺乳類細胞である、請求項1〜17のいずれか一項記載の方法。
- 前記宿主細胞が、哺乳類細胞である、請求項18記載の方法。
- 前記哺乳類細胞が、チャイニーズハムスター卵巣(CHO細胞)、NS0骨髄腫細胞、SP2細胞、COS細胞、および乳腺上皮細胞からなる群から選択される、請求項19記載の方法。
- 前記宿主細胞が、内因性のジヒドロ葉酸還元酵素を欠いている(dhfr − )、請求項20記載の方法。
- 前記第1の核酸または前記第2の核酸が、DHFRタンパク質をさらにコードする、請求項21記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492617P | 2011-06-02 | 2011-06-02 | |
US61/492,617 | 2011-06-02 | ||
US201161498266P | 2011-06-17 | 2011-06-17 | |
US61/498,266 | 2011-06-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014513732A Division JP6104897B2 (ja) | 2011-06-02 | 2012-06-01 | Fcレセプター結合タンパク質 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018085040A Division JP6638018B2 (ja) | 2011-06-02 | 2018-04-26 | Fcレセプター結合タンパク質 |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2017169559A JP2017169559A (ja) | 2017-09-28 |
JP2017169559A5 true JP2017169559A5 (ja) | 2017-12-07 |
JP6334763B2 JP6334763B2 (ja) | 2018-05-30 |
JP6334763B6 JP6334763B6 (ja) | 2018-07-11 |
Family
ID=47259886
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014513732A Active JP6104897B2 (ja) | 2011-06-02 | 2012-06-01 | Fcレセプター結合タンパク質 |
JP2017037848A Active JP6334763B6 (ja) | 2011-06-02 | 2017-03-01 | Fcレセプター結合タンパク質 |
JP2018085040A Active JP6638018B2 (ja) | 2011-06-02 | 2018-04-26 | Fcレセプター結合タンパク質 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014513732A Active JP6104897B2 (ja) | 2011-06-02 | 2012-06-01 | Fcレセプター結合タンパク質 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018085040A Active JP6638018B2 (ja) | 2011-06-02 | 2018-04-26 | Fcレセプター結合タンパク質 |
Country Status (14)
Country | Link |
---|---|
US (6) | US9359438B2 (ja) |
EP (2) | EP2714084B1 (ja) |
JP (3) | JP6104897B2 (ja) |
KR (1) | KR102014554B1 (ja) |
CN (2) | CN103619353B (ja) |
AU (2) | AU2012262007B2 (ja) |
BR (1) | BR112013030352B1 (ja) |
CA (1) | CA2837527C (ja) |
ES (1) | ES2748583T3 (ja) |
HK (2) | HK1195260A1 (ja) |
IL (1) | IL229618B (ja) |
MX (1) | MX343659B (ja) |
SG (2) | SG195025A1 (ja) |
WO (1) | WO2012167039A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101837329B1 (ko) * | 2008-04-25 | 2018-03-09 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
CA2837527C (en) | 2011-06-02 | 2019-05-28 | Dyax Corp. | Fc receptor binding proteins |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
EP4053560A1 (en) | 2013-11-26 | 2022-09-07 | The Brigham and Women's Hospital, Inc. | Compositions and methods for modulating an immune response |
MX2016014210A (es) * | 2014-04-30 | 2017-05-01 | Hanall Biopharma Co Ltd | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. |
US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
LT3250610T (lt) * | 2015-01-30 | 2023-09-25 | Momenta Pharmaceuticals, Inc. | Fcrn antikūnai ir jų panaudojimo būdai |
EA201892427A1 (ru) | 2016-04-25 | 2019-10-31 | ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ | |
SG11201900813RA (en) * | 2016-07-29 | 2019-02-27 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
EP3548320B1 (en) | 2016-12-01 | 2022-12-07 | SABIC Global Technologies B.V. | Hybrid composite tailgate |
AU2018386193A1 (en) | 2017-12-13 | 2020-06-25 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
KR20210105873A (ko) * | 2018-07-20 | 2021-08-27 | 모멘타 파머슈티컬스 인코포레이티드 | Fcrn 항체 조성물 |
KR20220050127A (ko) * | 2019-07-23 | 2022-04-22 | 상하이테크 유니버시티 | Asic1 채널 안타고니스트 항체 |
JP2023531451A (ja) | 2020-06-17 | 2023-07-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子療法患者の治療のための組成物及び方法 |
US11926669B2 (en) | 2022-05-30 | 2024-03-12 | Hanall Biopharma Co., Ltd. | Anti-FcRn antibody or antigen binding fragment thereof with improved stability |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
DE2901218A1 (de) | 1979-01-13 | 1980-07-17 | Byk Gulden Lomberg Chem Fab | Ung von theophyllin |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ES2035317T5 (es) | 1987-11-09 | 1998-03-16 | Becton Dickinson Co | Metodo para analizar celulas hematopoyeticas en una muestra. |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
US5179107A (en) | 1990-09-07 | 1993-01-12 | Schering Corporation | Antiviral quinolinone compounds |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
CA2087413A1 (en) | 1992-01-17 | 1993-07-18 | Joseph R. Lakowicz | Fluorescent energy transfer immunoassay |
SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
KR100566859B1 (ko) | 1997-01-21 | 2006-04-03 | 제너럴 하스피톨 코포레이션 | Rna-단백질 융합물을 이용한 단백질의 선별 |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US6960178B2 (en) | 2000-02-02 | 2005-11-01 | Xepmed, Inc. | Apparatus for enhanced plasmapheresis and methods thereof |
US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
ATE434040T1 (de) | 2001-10-01 | 2009-07-15 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
US20040005709A1 (en) | 2001-10-24 | 2004-01-08 | Hoogenboom Henricus Renerus Jacobus Mattheus | Hybridization control of sequence variation |
CA2478169C (en) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
JP2007501847A (ja) * | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己/同種免疫状態の治療用抗FcRn抗体 |
JP2008538919A (ja) * | 2005-04-29 | 2008-11-13 | ザ ジャクソン ラボラトリー | FcRn抗体およびその使用 |
CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
US20070181136A1 (en) | 2006-02-08 | 2007-08-09 | Gelb Michael L | Oral appliance |
US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
KR101837329B1 (ko) | 2008-04-25 | 2018-03-09 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
US8537763B2 (en) | 2008-06-30 | 2013-09-17 | Motorola Mobility Llc | Frame allocation to support legacy wireless communication protocols on uplink transmission |
WO2010008051A1 (ja) * | 2008-07-16 | 2010-01-21 | 株式会社医学生物学研究所 | 抗ヒトclcp1抗体とその用途 |
UY32341A (es) * | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
WO2010107110A1 (ja) * | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
CA2837527C (en) | 2011-06-02 | 2019-05-28 | Dyax Corp. | Fc receptor binding proteins |
US11149094B2 (en) | 2017-06-05 | 2021-10-19 | Janssen Biotech, Inc. | Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations |
MA52790A (fr) | 2018-06-08 | 2021-04-14 | Argenx Bvba | Compositions et méthodes de traitement de la thrombopénie immune |
-
2012
- 2012-06-01 CA CA2837527A patent/CA2837527C/en active Active
- 2012-06-01 AU AU2012262007A patent/AU2012262007B2/en active Active
- 2012-06-01 MX MX2013013832A patent/MX343659B/es active IP Right Grant
- 2012-06-01 WO PCT/US2012/040409 patent/WO2012167039A1/en active Application Filing
- 2012-06-01 EP EP12793948.6A patent/EP2714084B1/en active Active
- 2012-06-01 BR BR112013030352A patent/BR112013030352B1/pt active IP Right Grant
- 2012-06-01 SG SG2013085204A patent/SG195025A1/en unknown
- 2012-06-01 KR KR1020137034618A patent/KR102014554B1/ko active IP Right Grant
- 2012-06-01 US US14/122,880 patent/US9359438B2/en active Active
- 2012-06-01 CN CN201280031902.0A patent/CN103619353B/zh active Active
- 2012-06-01 EP EP15167896.8A patent/EP2966089B1/en active Active
- 2012-06-01 JP JP2014513732A patent/JP6104897B2/ja active Active
- 2012-06-01 CN CN201510926183.4A patent/CN105622754B/zh active Active
- 2012-06-01 ES ES12793948T patent/ES2748583T3/es active Active
- 2012-06-01 SG SG10201604493TA patent/SG10201604493TA/en unknown
-
2013
- 2013-11-25 IL IL229618A patent/IL229618B/en active IP Right Grant
-
2014
- 2014-08-29 HK HK14108820.3A patent/HK1195260A1/zh unknown
- 2014-10-08 HK HK16100888.7A patent/HK1213905A1/zh unknown
-
2016
- 2016-04-27 US US15/139,784 patent/US9862768B2/en active Active
-
2017
- 2017-03-01 JP JP2017037848A patent/JP6334763B6/ja active Active
- 2017-09-21 AU AU2017232160A patent/AU2017232160B2/en active Active
- 2017-12-04 US US15/830,998 patent/US10479834B2/en active Active
-
2018
- 2018-04-26 JP JP2018085040A patent/JP6638018B2/ja active Active
-
2019
- 2019-10-07 US US16/594,218 patent/US11014988B2/en active Active
-
2021
- 2021-03-17 US US17/203,816 patent/US11739152B2/en active Active
-
2023
- 2023-07-06 US US18/347,626 patent/US20240124593A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017169559A5 (ja) | ||
US20230242651A1 (en) | Stable antibody variable domain framework combinations | |
HRP20201993T1 (hr) | Protutijela protiv pd-1 | |
JP2020508655A5 (ja) | ||
JP2020504101A5 (ja) | ||
JP2020519308A5 (ja) | ||
KR102286053B1 (ko) | 신규한 항체 기본구조 | |
RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
CN104968685A (zh) | 异源二聚免疫球蛋白的纯化 | |
US11319371B2 (en) | Anti-CD3 antibodies | |
RU2011153932A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ | |
JP2023088986A (ja) | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 | |
JP2018121657A5 (ja) | ||
HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
JP2020524510A5 (ja) | ||
JP2012514997A5 (ja) | ||
JP2019504617A5 (ja) | ||
JP2012531922A5 (ja) | Toll様受容体2へのヒト化抗体またはその抗原結合部位 | |
HRP20220787T1 (hr) | Protutijela protiv garp-tgf-beta | |
RU2013119957A (ru) | Человеческие антитела к онкостатину м и способы их применения | |
RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
JP2015508056A5 (ja) | ||
JP2016518333A5 (ja) | ||
WO2018224441A1 (en) | Novel anti-cd3 antibodies | |
US11365240B2 (en) | Anti-HSA antibodies |